埃托米达注射对苏奇尼尔胆诱导的结的作用
1Department of Anesthesiology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Clinical therapeutics
|February 24, 2026
概括
在顺胆之前服用埃托米达特显著减少肌肉结和术后肌痛. 这项随机试验发现,以托米达注射有效地减轻了顺胆的副作用,而不会影响患者的血液动力学.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
背景情况:
- 苏奇尼尔胆是一种脱极化神经肌肉阻断剂,通常用于快速序列输管.
- 肌肉结和术后肌痛是顺胆的常见副作用.
- 寻求预治疗策略来减轻这些不良影响.
研究的目的:
- 评估埃托米达作为治疗前剂的疗效,以减少基尼尔胆诱导的结.
- 评估埃托米达前期治疗对术后肌痛发生率的影响.
主要方法:
- 一项随机对照试验,涉及100名接受选择性声带手术的成年患者.
- 患者在埃托米达 (0.2毫克/公斤) 后15秒内接受了即时的顺胆或顺胆.
- 主要结局是结的严重程度;次要结局包括肌痛发病率和血液动力学变化.
主要成果:
- 在服用顺胆之前接受埃托米达的组显著降低了结症的严重程度 (P = 0.005).
- 在直接服用埃托米达的组中观察到术后肌痛的发病率较低 (P = 0.031).
- 没有注意到输管条件或其他不良影响的显著差异.
结论:
- 在顺胆 (2毫克/公斤) 之前立即注射埃托米达 (0.2毫克/公斤) 有效地减少了结和术后肌痛.
- 这种预治疗策略似乎是安全的,不会影响输管条件或血液动力学.
更多相关视频
相关概念视频
Depolarizing Blockers: Pharmocokinetics
658
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
658
Depolarizing Blockers: Mechanism of Action
3.1K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.1K
Skeletal Muscle Relaxants: Adverse Effects
955
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
955
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.2K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.2K


